Drug
Ensifentrine Twice Daily Plus Placebo
Ensifentrine Twice Daily Plus Placebo: highest development phase Phase 2, developed by Merck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium NCT03937479 | Phase 2 | COPD |
Latest
No recent events.
Follow Ensifentrine Twice Daily Plus Placebo on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.